matrix tablet

Monoammonium glycyrrhizinate was determined it has anti-viral activity in case of hepatitis A, B, C, D. We have developed matrix tablet contained monoammonium glycyrrhizinate by previous study. The objective of the study was to evaluate drug release of matrix tablet in vivo  and determinate its stability. In the present study was evaluated in vivo drug release of the matrix tablet. Stability testing was determinated by long term and accelerated method by such criteria’s: appearance, weight variation, biological active compound, hardness, friability, dissolution and microbiological contamination. The Cmax (µg/ml), Tmax (h), AUC0-t (µg h/ml) of Glycyron tablet and Licozinat matrix tablet were determined in vivo. Stability of the matrix tablet was determined. Licozinat matrix tablet was released drug by prolonged time by in vitro. In vivo pharmacokinetic study in rabbits confirmed the prolonged release by showing increase in bioavailability for matrix tablet compared to Glycyron tablet. Licozinat matrix tablet was stable for 12 months. Stability testing of matrix tablet is continuing by long term method.

The objective of work was to prepare and characterize Levetiracetam matrix tablet using Polyethylene oxides (PEO 301, PEO coagulant and PEO 303) by wet granulation technique using variable concentrations of PEO 301, PEO coagulant and PEO 303. Total 12 formulations were prepared and optimized formulation were evaluated by Differential scanning Calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and The results obtained showed that the formulations of Levetiracetam prepared with combination PEO 303 (T10) has controlled release over 12 hrs.

The present study focuses on developing sustained release matrix tablets of Ibrutinib aiming to increase the therapeutic efficacy, reduce the frequency of administration and to improve the patient compliance. Sustained release matrix tablets of Ibrutinib, were developed by using different drug polymer ratios HPMC phthalate, Eudragit L 100, Eudragit S 100 as matrix former. All lubricated formulations were compressed by direct compression and by wet granulation method. Compressed tablets were evaluated for uniformity of weight, content of active ingredient, friability, hardness, thickness, in-vitro dissolution, and swelling index. All the formulation showed compliance with pharmacopoeial standards. Among the different formulation, B8 showed sustained release of drug for 12 hours with 86.55% release. The selected formulation (B8) was subjected to stability studies for three months at 25°C/60% RH, 30°C/65% RH and 40°C/75% RH and showed stability with respect to release pattern and all physical parameters. The regression coefficient value of Higuchi plot was found to be 0.9925 that showed that drug was released by diffusion mechanism. The slope value of korsmeyer-peppas equation was found to be 0.5062 which indicating that drug was released by non-fickian release mechanism. The R2 value for Hixson Crowell plot was found to be 0.9919 which indicates that drug release was limited by drug particle dissolution rate and erosion of the polymer matrix. Thus, drug in combination with Eudragit S 100 were found to be effective in retarding the release of Ibrutinib.

Gum odina, a natural polymer of carbohydrate moiety, has already been shown its potential as pharmaceutical excipient as a binder in tablet dosage form and also as an emulsifying agent but very little data are available regarding the use of it as controlled release polymer. In the present study the objective was to investigate the potential use of gum odina as natural release retarding material in sustained release drug delivery system (matrix tablet) using tramadol hydrochloride as a model drug. Tablet containing tramadol hydrochloride was prepared using gum odina and further coated with Eudragit L 100 to prevent its release in stomach. The prepared tablets were evaluated for physical characterization and in-vitro drug release. The results of this study has proven the suitability of using gum odina as an alternative to existing natural polymer in the field of controlled delivery of drug with a significant effect on drug release and desired release rate of drug from tablets.

The aim of this investigation was to develop and optimize Metformin Hydrochloride matrix tablets for sustained release application. The sustained release matrix tablet of Metformin Hydrochloride was prepared by wet granulation technique using Tamarind pulp polysaccharide. The polysaccharides obtained after extracted from natural source and evaluated for their colour, viscosity and pH. The prepared tablet was evaluated for their hardness, friability, drug content, In vitro dissolution, swelling studies. In vitro drug release profiles of Metformin Hydrochloride Tablet using Tamarind pulp polysaccharide formulation release of drug from the Tablet exhibited a sustained & controlled pattern over an extended time period. .The tablet formulation TF-1 was found to release the drug of about 95% after 12 hrs, The tablet formulation TF-5 was found to release the drug of about 70% after 12 hrs, thus concluded to have sustained drug release for longer period of time in sustained and controlled pattern when compared to other tablet formulations. Using Higuchi’s Model and the Korsmeyer equation, the drug release mechanism from the sustained release tablets was found to be Anomalous (non-Fickian) diffusion. Compatibility study confirmed that interactions do not exist between the drug and polymer.

  The present study was undertaken to investigate the release retardant potential of Borassus flabellifer mucilage in tablet formulations. In the present study six batches of diclofenac sodium matrix tablets were prepared by wet granulation method with different concentrations of BFM (2.5, 5, 7.5,10 and 12.5%w/w) and compared with guar gum as standard release retardant polymer. The tablets had uniform physical appearance, average weight, drug content, and adequate hardness. The results of in vitro release revealed that as the proportion of mucilage in the matrix was increased there was a corresponding decrease in the release of drug. Among the formulations studied formulation F5 containing BFM in the concentration of 12.5% showed sustained and required dissolution profile of drug for 12hrs with cumulative percent release of 98%. Further, the matrix tablets were found to release the drug by diffusion coupled with erosion mechanism. The swelling studies revealed that, as the proportion of mucilage in tablets was increased, there was a corresponding increase in percent swelling of tablets. The SEM photomicrographs showed both pores and gelling structures were present on the surface of tablets indicates the combination of diffusion and erosion mechanism in the release of diclofenac. No chemical interaction between drug, mucilage and mixture of mucilage/drug was seen as confirmed by DSC and IR studies. Optimized formulation (F5) showed no change in physical appearance, drug content, or in dissolution pattern after storage at 40±2°C and 75±5% RH for 3 months.